incretin hormone glp-1 hormones and obesity - Alcaino - 2025 - The Journal of Physiology The Incretin Impact: a new

As employers design their coverage plans, Huang says they are also increasingly paying close attention to how employees are using the drugs, persistence and discontinuation rates, and outcomes when the drugs are stopped

Its a glucagon-like peptide-1 (GLP-1) receptor agonist that works by mimicking a hormone in the body that helps control blood sugar, insulin levels, digestion, and feelings of satiety

These drugs also have low uptake (less than 2% in the USA) due to several factors, including patients reluctance to seek treatment, lack of addiction training among healthcare providers and considerable stigma surrounding AUD and addiction. - Lorenzo Leggio, et al, Nature Medicine, December 2023 Based on the percentage of people in the United States with alcohol use disorder (11% or ~29.5 million) and the number of people who have received medication for alcohol use disorder in the past year (624,000) and the number of people taking GLP-1 drugs (7 percent of American adults or 18 million), we roughly estimate that more than 3 times as many people with AUD have been incidentally prescribed a GLP-1 in the past year than have been prescribed a medication that is FDA indicated for alcohol use disorder (~2 million vs 624,000, and these groups may overlap)

Dual agonist drugs may also lead to a superior metabolism because the medication targets multiple signaling pathways simultaneously

Our studies show that GLP-1 receptor agonists strongly activate the hypothalamic pituitary adrenal (HPA) axis the system that produces stress hormones such as cortisol in humans and corticosterone in preclinical models